1. Home
  2. ELE vs TRDA Comparison

ELE vs TRDA Comparison

Compare ELE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELE

Elemental Royalty Corporation Common Stock

N/A

Current Price

$15.58

Market Cap

354.2M

Sector

N/A

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$9.79

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELE
TRDA
Founded
N/A
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
354.2M
386.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ELE
TRDA
Price
$15.58
$9.79
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$24.50
AVG Volume (30 Days)
138.1K
298.3K
Earning Date
03-30-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
145.82
N/A
EPS
0.21
N/A
Revenue
$33,115,000.00
$61,520,000.00
Revenue This Year
$146.47
N/A
Revenue Next Year
$57.23
N/A
P/E Ratio
$167.67
N/A
Revenue Growth
124.30
N/A
52 Week Low
$7.43
$4.93
52 Week High
$20.19
$21.79

Technical Indicators

Market Signals
Indicator
ELE
TRDA
Relative Strength Index (RSI) N/A 69.98
Support Level N/A $8.17
Resistance Level N/A $10.75
Average True Range (ATR) 0.00 0.67
MACD 0.00 0.07
Stochastic Oscillator 0.00 73.52

Price Performance

Historical Comparison
ELE
TRDA

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: